Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein

Leukemia. 2014 Apr;28(4):961-4. doi: 10.1038/leu.2014.21. Epub 2014 Jan 14.

Authors

S Shukla¹, E E Chufan¹, S Singh², A P Skoumbourdis³, K Kapoor¹, M B Boxer³, D Y Duveau³, C J Thomas³, T T Talele², S V Ambudkar¹

Affiliations

¹ Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
² Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St John's University, Queens, NY, USA.
³ NIH Chemical Genomics Center, National Center for Advancing Translational Sciences, Rockville, MD, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Intramural

MeSH terms

ATP Binding Cassette Transporter, Subfamily B, Member 1 / chemistry*
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
Benzamides / metabolism
Binding Sites
Fusion Proteins, bcr-abl / antagonists & inhibitors*
Humans
Imatinib Mesylate
Piperazines / metabolism
Protein Kinase Inhibitors / metabolism*
Pyrimidines / metabolism*

Substances

ATP Binding Cassette Transporter, Subfamily B, Member 1
Benzamides
Piperazines
Protein Kinase Inhibitors
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl
nilotinib

Grants and funding